Table 2.
Prognostic Analyses (Univariate)
| PFS |
OS |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Subtypes (versus PTCL-NOS) | ||||||
| ATLL | 1.03 | 0.56–1.91 | 0.91 | 1.21 | 0.63–2.32 | 0.56 |
| NK/TCL | 0.50 | 0.25–1.00 | 0.05 | 0.47 | 0.20–1.09 | 0.07 |
| EATCL | 0.97 | 0.42–2.23 | 0.93 | 0.84 | 0.30–2.31 | 0.73 |
| HSL | 1.60 | 0.58–4.40 | 0.36 | 1.43 | 0.45–4.56 | 0.55 |
| SPTCL | 0.33 | 0.08–1.34 | 0.12 | 0.51 | 0.12–2.08 | 0.35 |
| t-CTCL | 3.32 | 1.21–9.15 | 0.02 | 0.85 | 0.21–3.48 | 0.82 |
| ALK+ ALCL | 0.44 | 0.22–0.88 | 0.02 | 0.30 | 0.12–0.74 | 0.009 |
| ALK− ALCL | 0.99 | 0.55–1.79 | 0.69 | 0.47 | 0.26–0.85 | 0.012 |
| AITL | 0.92 | 0.60–1.41 | 0.35 | 0.52 | 0.32–0.82 | 0.005 |
| Prognostic scores | ||||||
| IPI | 1.28 | 1.13–1.45 | 0.0001 | 1.59 | 1.35–1.86 | <.0001 |
| PIT | 1.25 | 1.08–1.45 | 0.004 | 1.47 | 1.22–1.77 | <.0001 |
| IPTCLP | 1.26 | 1.06–1.50 | 0.002 | 1.51 | 1.23–1.86 | <.0001 |
| Clinical/treatment factors | ||||||
| Gender (Female versus male) | 0.86 | 0.65–1.14 | 0.29 | 0.70 | 0.49–1.00 | 0.047 |
| History of CAD | 1.44 | 0.97–2.16 | 0.07 | 2.06 | 1.32–3.21 | 0.001 |
| Hypoalbuminemia | 1.50 | 1.08–2.08 | 0.016 | 1.86 | 1.24–2.78 | 0.003 |
| Elevated LDH | 1.50 | 1.08–2.09 | 0.02 | 1.90 | 1.26–2.87 | 0.002 |
| Stage (1/2 versus 3/4)a | 0.55 | 0.39–0.78 | 0.0008 | 0.40 | 0.25–0.65 | 0.0002 |
| HyperCVAD/MA frontline | 0.53 | 0.29–0.72 | 0.05 | 0.49 | 0.24–0.70 | 0.098 |
| Consolidative RT | 0.68 | 0.47–0.97 | 0.03 | 0.55 | 0.34–0.89 | 0.015 |
| Consolidative SCT | 0.48 | 0.27–0.84 | 0.01 | 0.48 | 0.24–0.98 | 0.044 |
aRemained significant on multivariate analysis.
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ALCL, anaplastic large-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; NK/TCL, NK/T-cell lymphoma; ATLL, adult T-cell leukemia/lymphoma; EATCL, enteropathy-associated T-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; HTCL, hepatosplenic T-cell lymphoma; t-CTCL, transformed cutaneous T-cell lymphoma; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; IPI, International Prognostic Index; PIT, Prognostic Index for T-cell lymphoma; IPTCLP, International peripheral T-cell lymphoma Project; LDH, lactate dehydrogenase; SCT, stem-cell transplantation; RT, radiotherapy.